2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12F.03 Trametinib in the Treatment of Patients with Metastatic Lung Adenocarcinoma Harboring NF1 Mutation

EP.12F.03 Trametinib in the Treatment of Patients with Metastatic Lung Adenocarcinoma Harboring NF1 Mutation

Pdf Summary

This study examined the use of trametinib, a MEK inhibitor, in treating four patients with metastatic non-small-cell lung cancer (NSCLC) harboring NF1 mutations, at the University Hospital Geneva. NF1 mutations, associated with neurofibromatosis type 1, have shown some promise in responding to trametinib in pre-clinical models, but data specific to NF1-mutated NSCLC is insufficient.<br /><br />The patients had several types of NF1 mutations, including splice acceptor variants and stop codon gains. Results from this small case study found that trametinib, used as a third-line treatment, failed to benefit these patients significantly. The treatment lasted up to nine weeks and was moderately well-tolerated, with no severe side effects halting the treatment. However, the best clinical outcome was only stable disease in one patient, and unfortunately, all patients passed away within three months of initiating the treatment.<br /><br />Notably, no concurrent alterations in the MAPK/ERK pathway were identified in these patients. This suggests that trametinib might not effectively target these alterations alone in NF1-mutated NSCLC.<br /><br />The study concludes that these findings do not support the routine use of trametinib for patients with NSCLC harboring NF1 mutations and indicate the need for comprehensive studies involving larger patient groups. Further research should include an in-depth analysis of all genes in the MAPK pathway to potentially identify patients who might derive more benefit from trametinib or similar treatments.

Asset Subtitle

Alfredo Addeo

Meta Tag

Speaker Alfredo Addeo

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

trametinib

MEK inhibitor

metastatic non-small-cell lung cancer

NSCLC

NF1 mutations

University Hospital Geneva

neurofibromatosis type 1

MAPK/ERK pathway

third-line treatment

clinical outcome